1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shelter Pharma Ltd.

Shelter Pharma Ltd.

BBSE:SHELTER
47.00
INR
0.00
(0.00%)
445.69MMarket Cap
Shelter Pharma Ltd.
BSE:SHELTER
(Bombay Stock Exchange)

Recent

price

47.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
2026
TTM
INR
25.93
19.45
25.92
31.55
34.62
43.82
44.03
- -
Revenue per Share
0.07
-0.21
1.58
4.54
5.36
6.26
5.43
- -
Basic EPS, GAAP
-0.28
-0.25
-0.08
-0.84
-2.43
2.4
-7.51
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.33
0.23
- -
Dividend per Share
6.04
6.19
7.72
12.59
30.98
36.96
46.13
46.13
Book Value per Share
6.04
6.19
7.72
12.59
30.97
36.95
45.85
45.85
Tangible Book Value per Share
12
12
12
11
12
12
17
14
Basic Weighted Avg Shares
301
225
301
362
400
507
731
- -
Sales/Revenue/Turnover
0.37
0.26
9.6
22.7
22.09
19.93
17.33
- -
Operating Margin (%)
1
1
2
2
2
3
4
- -
Depreciation Expense
1
-2
18
52
62
72
90
- -
Net Income, GAAP
24.32
- -
26.68
25.44
25.14
25.21
26.16
- -
Effective Tax Rate (%)
0.27
-1.06
6.11
14.4
15.49
14.29
12.34
- -
Profit Margin (%)
46
50
61
125
282
287
480
480
Working Capital
- -
- -
1
5
6
9
5
5
LT Debt
70
72
89
145
358
427
766
766
Total Equity
- -
- -
22.42
37.47
23.44
18.28
15.04
- -
Return on Invested Capital (%)
- -
- -
23.21
41.03
24.12
18.06
14.97
- -
Return on Capital (%)
- -
-3.38
22.84
44.35
24.62
18.43
15.13
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
1
4
3
LT Borrowings
9
8
5
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
17
Market Capitalization
418
515
446

Working Capital

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
333
423
550
Cash, Cash Equivalents & STI
34
53
11
Accounts Receivable, Net
95
109
118
Inventories
129
167
244
Total Current Liabilities
46
53
70
Payables & Accruals
- -
- -
- -
ST Debt
1
4
3
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
66.5%
79.38%
Free Cash Flow
- -
75.14%
-550.17%
Net Income, GAAP
- -
-125.06%
24.73%
Sales/Revenue/Turnover
- -
27.12%
44.36%
Total Cash Common Dividend
- -
- -
-0.97%

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
400
2025
- -
- -
507
2026
- -
- -
731

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
5.36
2025
- -
- -
6.26
2026
- -
- -
5.43

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
0.33
2026
- -
- -
0.23
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shelter Pharma Ltd. manufactures and markets herbal Ayurvedic medicines and formulations for human healthcare, veterinary care, and poultry health in India. The company offers an extensive portfolio of over-the-counter and ethical pharmaceutical products, including for human use Adalpin-SP Tablet, Alkaliser Syrup, B-Kleen Liquid and Tablets for blood purification and skin health, Baldeepak Syrup, Banatone Syrup, Beta Gulcan, Bipinyl Capsule, Chymocure, Cocoment Ointment, Cough Nal Syrup, Dia Dys Tablet, D3 Cure, Diabetone Tablet for diabetes management, Emune 19 Syrup and Capsule for immunity boosting, Freshol Hand Cleanser, Happy Forte Capsule for vitality, Gynoshel Liquid, Gasoshel Tablet for gas and acidity relief, Lemon Barley Water for kidney health and detoxification, Livodin 12 Syrup for liver support, Sherolax Laxative Tablet, Stonyl Tablet for kidney stones, and Wormishel Tablet; for veterinary and poultry use Anical Oral, Bijrol Liquid, Biotone Plus Liquid, Bovi Cal-P, Buta-B Bolus, Cal Boost Vet, Calci D Plus, Gasoshel Tablet, Stonyl Tablet, and Sherolax Tablets, among others. Shelter Pharma Ltd., founded in 1965 and headquartered in Ahmedabad, Gujarat, operates GMP, HACCP, and ISO 9001:2015 certified facilities focused on in-house R&D and Ayurvedic expertise, serving domestic markets through pharma distributors, retailers, and veterinarians. In recent developments, the company converted multiple tranches of convertible warrants into equity shares, including 7.35 lakh warrants at Rs 42.25 per share in November 2025 raising Rs 2.33 crore from promoters Shakil Nisarahmed Sabugar and Mustaqim Nisarahmed Sabugar, 11.28 lakh warrants in October 2025 raising Rs 3.57 crore, and 13.14 lakh warrants earlier in October 2025 raising Rs 4.16 crore, increasing paid-up capital to Rs 16.33 crore; it also secured a purchase order from Taha Drugs & Chemicals Co. for Joemega Capsule and Vitamins Tablets in November 2025 and received funding approvals for up to Rs 385 million through warrants in mid-2025.